Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Overview | 6 | 4 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Products under Development by Stage of Development | 7 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Products under Development by Therapy Area | 8 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Products under Development by Indication | 9 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Products under Development by Companies | 12 | 2 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Products under Development by Universities/Institutes | 14 | 2 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Companies Involved in Therapeutics Development | 22 | 2 |
| Advaxis, Inc. | 22 | 1 |
| Akshaya Bio Inc. | 23 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Drug Profiles | 24 | 13 |
| DTP-348 Drug Profile | 24 | 1 |
| ESE-15-ol Drug Profile | 25 | 1 |
| Lm-LLO-CA9 Drug Profile | 26 | 2 |
| Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma Drug Profile | 28 | 1 |
| SLC-0111 Drug Profile | 29 | 1 |
| SLC-0121 Drug Profile | 30 | 1 |
| Small Molecules to Inhibit Carbonic Anhydrase IX for Cancer Drug Profile | 31 | 1 |
| Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma Drug Profile | 32 | 1 |
| Vaccine to Target CA9 for Cancer Drug Profile | 33 | 1 |
| Vaccine to Target HER2 and CA9 for Breast Cancer Drug Profile | 34 | 2 |
| WBI-5111 Drug Profile | 36 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Dormant Projects | 37 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Discontinued Products | 38 | 1 |
| Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) Featured News &Press Releases | 39 | 1 |
| Dec 04, 2014: SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours | 39 | 1 |
| Appendix | 40 | 2 |
| Methodology | 40 | 1 |
| Coverage | 40 | 1 |
| Secondary Research | 40 | 1 |
| Primary Research | 40 | 1 |
| Expert Panel Validation | 40 | 1 |
| Contact Us | 40 | 1 |
| Disclaimer | 41 | 1 |